Cargando…

Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis

To assess the efficacy and safety of non-biological therapies in patients with axial spondyloarthritis (axSpA) to inform the update of the Assessment of SpondyloArthritis international Society (ASAS)/European League Against Rheumatism (EULAR) recommendations for the management of axSpA. A systematic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Regel, Andrea, Sepriano, Alexandre, Baraliakos, Xenofon, van der Heijde, Désirée, Braun, Jürgen, Landewé, Robert, Van den Bosch, Filip, Falzon, Louise, Ramiro, Sofia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2017
Materias:	Spondyloarthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278330/ https://www.ncbi.nlm.nih.gov/pubmed/28176966 http://dx.doi.org/10.1136/rmdopen-2016-000397

Ejemplares similares

Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis
por: Sepriano, Alexandre, et al.
Publicado: (2017)

Biological DMARDs and disease modification in axial spondyloarthritis: a review through the lens of causal inference
por: Sepriano, Alexandre, et al.
Publicado: (2021)

Role of vertebral corner inflammation and fat deposition on MRI on syndesmophyte development detected on whole spine low-dose CT scan in radiographic axial spondyloarthritis
por: Stal, Rosalinde, et al.
Publicado: (2022)

Do fatty lesions explain the effect of inflammation on new syndesmophytes in patients with radiographic axial spondyloarthritis? Results from the SIAS cohort and ASSERT trial
por: Stal, Rosalinde, et al.
Publicado: (2023)

Good construct validity of the CT Syndesmophyte Score (CTSS) in patients with radiographic axial spondyloarthritis
por: Stal, Rosalinde, et al.
Publicado: (2023)

Imaging Outcomes for Axial Spondyloarthritis and Sensitivity to Change: A Five‐Year Analysis of the DESIR Cohort
por: Sepriano, Alexandre, et al.
Publicado: (2022)

Inflammation of the Sacroiliac Joints and Spine and Structural Changes on Magnetic Resonance Imaging in Axial Spondyloarthritis: Five‐Year Data From the DESIR Cohort
por: Sepriano, Alexandre, et al.
Publicado: (2021)

Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis
por: Kiltz, Uta, et al.
Publicado: (2020)

Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction
por: Landewé, Robert BM, et al.
Publicado: (2020)

Low-dose CT hounsfield units: a reliable methodology for assessing vertebral bone density in radiographic axial spondyloarthritis
por: Marques, Mary Lucy, et al.
Publicado: (2022)

Tumor Necrosis Factor Inhibitors Reduce Spinal Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: A Longitudinal Analysis From the Alberta Prospective Cohort
por: Sepriano, Alexandre, et al.
Publicado: (2021)

Clinical characteristics of non-radiographic versus radiographic axial spondyloarthritis in Asia and non-radiographic axial spondyloarthritis in other regions: results of the cross-sectional ASAS-COMOSPA study
por: Kishimoto, Mitsumasa, et al.
Publicado: (2021)

Inflammation, bone loss and 2-year bone formation at the same vertebra in axial spondyloarthritis: a multilevel MRI and low-dose CT analysis
por: Marques, Mary Lucy, et al.
Publicado: (2023)

Determinants of the Physician Global Assessment of Disease Activity and Influence of Contextual Factors in Early Axial Spondyloarthritis
por: Hirano, Fumio, et al.
Publicado: (2022)

Is radiographic progression in radiographic axial spondyloarthritis related to matrix metalloproteinase degradation of extracellular matrix?
por: Siebuhr, Anne Sofie, et al.
Publicado: (2018)

Geographical prevalence of family history in patients with axial spondyloarthritis and its association with HLA-B27 in the ASAS-PerSpA study
por: Boel, Anne, et al.
Publicado: (2022)

5-year follow-up of spinal and sacroiliac MRI abnormalities in early axial spondyloarthritis: data from the DESIR cohort
por: Madari, Queeny, et al.
Publicado: (2020)

Uncovering the heterogeneity of disease impact in axial spondyloarthritis: bivariate trajectories of disease activity and quality of life
por: Imkamp, Maike, et al.
Publicado: (2018)

Spinal Radiographic Progression in Early Axial Spondyloarthritis: Five‐Year Results From the DESIR Cohort
por: Ramiro, Sofia, et al.
Publicado: (2019)

Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis
por: López-Medina, Clementina, et al.
Publicado: (2019)

Sick leave in early axial spondyloarthritis: the role of clinical and socioeconomic factors. Five-year data from the DESIR cohort
por: Nikiphorou, Elena, et al.
Publicado: (2021)

Test–retest reliability of outcome measures: data from three trials in radiographic and non-radiographic axial spondyloarthritis
por: Boel, Anne, et al.
Publicado: (2021)

Evaluation of multiple referral strategies for axial spondyloarthritis in the SPondyloArthritis Caught Early (SPACE) cohort
por: Abawi, Ozair, et al.
Publicado: (2017)

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
por: Dougados, Maxime, et al.
Publicado: (2020)

Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a 52‐Week, Randomized, Controlled Trial
por: Walsh, Jessica A., et al.
Publicado: (2022)

No relationship between bone mineral density and syndesmophyte formation at the same level in the lumbar spine of patients with radiographic axial Spondyloarthritis
por: Marques, Mary Lucy, et al.
Publicado: (2020)

Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials
por: van der Heijde, Désirée, et al.
Publicado: (2023)

Measuring impairments of functioning and health in patients with axial spondyloarthritis by using the ASAS Health Index and the Environmental Item Set: translation and cross-cultural adaptation into 15 languages
por: Kiltz, U, et al.
Publicado: (2016)

Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis
por: Rudwaleit, M., et al.
Publicado: (2016)

Improvements in workplace and household productivity with certolizumab pegol treatment in axial spondyloarthritis: results to week 96 of a phase III study
por: van der Heijde, Désirée, et al.
Publicado: (2018)

A Fifty‐Two–Week, Randomized, Placebo‐Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis
por: Deodhar, Atul, et al.
Publicado: (2019)

Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study
por: van der Heijde, Désirée, et al.
Publicado: (2022)

Does body mass index (BMI) influence the Ankylosing Spondylitis Disease Activity Score in axial spondyloarthritis?: Data from the SPACE cohort
por: Rubio Vargas, Roxana, et al.
Publicado: (2016)

Maternal and infant outcomes in pregnancies of women with axial spondyloarthritis compared with matched controls: results from nationwide health insurance data
por: Redeker, Imke, et al.
Publicado: (2022)

Is it Useful to Repeat Magnetic Resonance Imaging of the Sacroiliac Joints After Three Months or One Year in the Diagnosis of Patients With Chronic Back Pain and Suspected Axial Spondyloarthritis?
por: Bakker, P. A. C., et al.
Publicado: (2019)

Measuring quality of life of patients with axial spondyloarthritis for economic evaluation
por: Hernandez Alava, Monica, et al.
Publicado: (2022)

Effect of Certolizumab Pegol Over Ninety-Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial
por: Sieper, J, et al.
Publicado: (2015)

Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study
por: Sieper, Joachim, et al.
Publicado: (2019)

Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study
por: López-Medina, Clementina, et al.
Publicado: (2021)

Is there a relationship between spondyloarthritis and periodontitis? A case–control study
por: Bautista-Molano, Wilson, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_mto2mi33odbo5iaknvsqli082j